Systems Biology Opens the Blackest Boxes
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Biotech Industry Forecast
The biotech industry experienced its share of stormy weather this year, from budget cuts and the fiscal cliff to Prometheus v. Mayo and a drop in VC funds, but there were a few sunny days here and there: FDA finally issued its draft guidance on the development and approval of biosimilar drugs, and two new obesity drugs were approved by FDA, the first in more than a decade. (For more on all of the above developments, click here.) So, what does your industry forecast look like for 2013—clear sailing ahead, or should sailors take warning?